Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Canadian biopharmaceutical company Bioniche Life Sciences has signed a definitive agreement to sell its injectibles manufacturing subsidiary Bioniche Pharma to US-based RoundTable Health Partners for a total deal value of approximately $33 million.
Subscribe to our email newsletter
The form of the deal includes a combination of $13.25 million cash, as well as debt assumption, minority ownership in the business going forward and deferred sale proceeds. The transaction was first announced on October 5, 2005 and is expected to close later this month.
Proceeds from the sale will go towards the company’s drug development programs including a cancer treatment planned to enter a pivotal phase III trial in superficial bladder cancer, and an E coli cattle vaccine that is nearing licensing.
“These two key projects require significant attention and investment at this late stage of their development,” said Graeme McRae, president & CEO of Bioniche Life Sciences.